Your browser doesn't support javascript.
loading
HIV risk behaviour, viraemia, and transmission across HIV cascade stages including low-level viremia: Analysis of 14 cross-sectional population-based HIV Impact Assessment surveys in sub-Saharan Africa.
Edun, Olanrewaju; Okell, Lucy; Chun, Helen; Bissek, Anne-Cecile Z; Ndongmo, Clement B; Shang, Judith D; Brou, Hermann; Ehui, Eboi; Ekra, Alexandre K; Nuwagaba-Biribonwoha, Harriet; Dlamini, Sindisiwe S; Ginindza, Choice; Eshetu, Frehywot; Misganie, Yimam G; Desta, Sileshi Lulseged; Achia, Thomas N O; Aoko, Appolonia; Jonnalagadda, Sasi; Wafula, Rose; Asiimwe, Fred M; Lecher, Shirley; Nkanaunena, Kondwani; Nyangulu, Mtemwa K; Nyirenda, Rose; Beukes, Anita; Klemens, Johannes O; Taffa, Negussie; Abutu, Andrew A; Alagi, Matthias; Charurat, Man E; Dalhatu, Ibrahim; Aliyu, Gambo; Kamanzi, Collins; Nyagatare, Celestine; Rwibasira, Gallican N; Jalloh, Mohamed F; Maokola, Werner M; Mgomella, George S; Kirungi, Wilford L; Mwangi, Christina; Nel, Jennifer A; Minchella, Peter A; Gonese, Gloria; Nasr, Melodie A; Bodika, Stephane; Mungai, Elisabeth; Patel, Hetal K; Sleeman, Katrina; Milligan, Kyle; Dirlikov, Emilio.
Afiliação
  • Edun O; MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
  • Okell L; MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.
  • Chun H; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Atlanta, Georgia, United States of America.
  • Bissek AZ; Division of Health Operations Research, Ministry of Public Health, Yaoundé, Cameroon.
  • Ndongmo CB; Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon.
  • Shang JD; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Yaoundé, Cameroon.
  • Brou H; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Yaoundé, Cameroon.
  • Ehui E; ICAP, Columbia University, Abidjan, Côte d'Ivoire.
  • Ekra AK; National AIDS Control Programme, Ministry of Health, Public Hygiene and Universal Health Coverage, Abidjan, Côte d'Ivoire.
  • Nuwagaba-Biribonwoha H; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Abidjan, Côte d'Ivoire.
  • Dlamini SS; ICAP at Columbia University and Department of Epidemiology, Mailman School of Public Health, Mbabane, Eswatini.
  • Ginindza C; Ministry of Health, Mbabane, Eswatini.
  • Eshetu F; Central Statistical Office, Mbabane, Eswatini.
  • Misganie YG; U.S. Centers for Disease Control and Prevention Division of Global HIV/TB, Center for Global Health, Addis Ababa, Ethiopia.
  • Desta SL; Ethiopian Public Health Institute, HIV/AIDS and TB Research Directorate, Addis Ababa, Ethiopia.
  • Achia TNO; School of Medicine, Zhejiang University, Hangzhou, China.
  • Aoko A; ICAP in Ethiopia, Mailman School of Public Health, Columbia University, Addis Ababa, Ethiopia.
  • Jonnalagadda S; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Nairobi, Kenya.
  • Wafula R; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Nairobi, Kenya.
  • Asiimwe FM; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Nairobi, Kenya.
  • Lecher S; National AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya.
  • Nkanaunena K; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Maseru, Lesotho.
  • Nyangulu MK; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Maseru, Lesotho.
  • Nyirenda R; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Lilongwe, Malawi.
  • Beukes A; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Lilongwe, Malawi.
  • Klemens JO; Department of HIV/AIDS, Ministry of Health, Lilongwe, Malawi.
  • Taffa N; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Windhoek, Namibia.
  • Abutu AA; Namibia Institute of Pathology Limited, Windhoek, Namibia.
  • Alagi M; Ministry of Health and Social Services, Windhoek, Namibia.
  • Charurat ME; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Abuja, Nigeria.
  • Dalhatu I; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Abuja, Nigeria.
  • Aliyu G; Center for International Health, Education, and Biosecurity (Ciheb), University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
  • Kamanzi C; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
  • Nyagatare C; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Abuja, Nigeria.
  • Rwibasira GN; National Agency for the Control of AIDS, Abuja, Nigeria.
  • Jalloh MF; ICAP, Columbia University, Kigali, Rwanda.
  • Maokola WM; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Kigali, Rwanda.
  • Mgomella GS; HIV, STIs, Viral Hepatitis & OVDC Department, Rwanda Biomedical Center, Kigali, Rwanda.
  • Kirungi WL; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Dar es Salaam, Tanzania.
  • Mwangi C; National AIDS Control Programme, Tanzania Ministry of Health, Dar es Salaam, Tanzania.
  • Nel JA; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Dar es Salaam, Tanzania.
  • Minchella PA; Ministry of Health, AIDS Control Programme, Kampala, Uganda.
  • Gonese G; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Kampala, Uganda.
  • Nasr MA; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Kampala, Uganda.
  • Bodika S; U.S. Centers for Disease Control and Prevention Division of Global HIV/TB, Center for Global Health, Lusaka, Zambia.
  • Mungai E; Zimbabwe Technical Assistance, Training and Education Center for Health (Zim-TTECH), Harare, Zimbabwe.
  • Patel HK; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Harare, Zimbabwe.
  • Sleeman K; Public Health Institute, Global Health Fellowship Program, United States of America.
  • Milligan K; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Atlanta, Georgia, United States of America.
  • Dirlikov E; U.S. Centers for Disease Control and Prevention - Division of Global HIV/TB, Center for Global Health, Atlanta, Georgia, United States of America.
PLOS Glob Public Health ; 4(4): e0003030, 2024.
Article em En | MEDLINE | ID: mdl-38573931
ABSTRACT
As antiretroviral treatment (ART) coverage for people living with HIV (PLHIV) increases, HIV programmes require up-to-date information about evolving HIV risk behaviour and transmission risk, including those with low-level viremia (LLV; >50 to ≤1000 copies/mL), to guide prevention priorities. We aimed to assess differences in sexual risk behaviours, distribution of viral load (VL) and proportion of transmission across PLHIV subgroups. We analysed data from Population-based HIV Impact Assessment surveys in 14 sub-Saharan African countries during 2015-2019. We estimated adjusted prevalence ratios (aPR) of self-reported HIV high-risk behaviour (multiple partners and condomless sex) across cascade stages via generalised estimation equations. We modelled the proportions of transmission from each subgroup using relative self-reported sexual risk, a Hill function for transmission rate by VL, and proportions within cascade stages from surveys and UNAIDS country estimates for 2010-2020. Compared to PLHIV with undetectable VL (≤50 copies/mL), undiagnosed PLHIV (aPR women 1.28 [95% CI 1.08-1.52]; men 1.61 [1.33-1.95]) and men diagnosed but untreated (2.06 [1.52-2.78]) were more likely to self-report high-risk sex. High-risk behaviour was not significantly associated with LLV. Mean VL was similar among undiagnosed, diagnosed but untreated, and on ART but non-suppressed sub-groups. Across surveys, undiagnosed and diagnosed but untreated contributed most to transmission (40-91% and 1-41%, respectively), with less than 1% from those with LLV. Between 2010 and 2020, the proportion of transmission from individuals on ART but non-suppressed increased. In settings with high ART coverage, effective HIV testing, ART linkage, and retention remain priorities to reduce HIV transmission. Persons with LLV are an increasing share of PLHIV but their contribution to HIV transmission was small. Improving suppression among PLHIV on ART with VL ≥1000 copies/mL will become increasingly important.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article